The Personalized Nutrition Boom Has a Quality Testing Problem

The global personalized nutrition market hit $11.8 billion in 2023 and is expanding at a compound annual rate of roughly 11.2%, according to Grand View Research. Every major supplement retailer — from bootstrapped direct-to-consumer startups to established brands with decades of shelf presence — is pivoting toward custom formulations driven by health quizzes, DNA test results, and subscription models. The promise is genuinely compelling: science-matched nutrients assembled around your specific biology.

The quality infrastructure hasn’t kept pace.

Most personalized supplement brands started as technology companies, subscription platforms, or wellness-lifestyle brands. Their core competency is user experience and customer acquisition, not GMP compliance or raw material qualification. And that’s where the problem starts — often quietly, often without anyone realizing there’s a gap, until there is.

”Custom” Doesn’t Mean “Exempt” — What 21 CFR Part 111 Actually Requires

This is the regulatory reality that a surprising number of personalized supplement companies haven’t internalized: FDA’s Current Good Manufacturing Practices for dietary supplements, codified in 21 CFR Part 111, apply equally to a 10,000-unit run of a standardized multivitamin and a 50-unit custom blend assembled for subscribers in a specific health cohort. There is no personalized-product exemption. None exists in the regulation, and FDA has given no indication one is coming.

Part 111.75 requires manufacturers to establish the identity of every dietary ingredient before it enters production. That means 100% of incoming ingredients must be tested — or, in limited circumstances, a COA from a pre-qualified supplier can be accepted after appropriate validation. When your formulation matrix changes week to week because customer profiles and ingredient pools are being updated by an algorithm, that supplier qualification program needs to be robust enough to absorb the variation. A qualification you conducted on a single ashwagandha source six months ago doesn’t automatically transfer to a new supplier you brought on to manage cost pressure.

Part 111.83 requires testing of finished batches against product specifications. When you have dozens of formulation variants in production simultaneously, the sampling burden and documentation requirements grow considerably. Most small and mid-sized personalized nutrition brands are managing this with a single contract manufacturer and a thin testing program that was never designed for variable-SKU production.

The FTC is also paying closer attention to this space. Claims tied to personalized recommendations — “your formula, based on your health profile” — invite heightened scrutiny if the underlying formulation can’t be verified to contain what the label says. That’s a second regulatory exposure point most brands aren’t thinking about.

Where Standard Testing Protocols Start to Break Down

Let me get specific about the technical challenges, because they’re not abstract — they show up in real lab data from real products.

Identity and authenticity. If your personalized supplement includes ashwagandha root extract, lion’s mane mushroom, rhodiola rosea, and a half-dozen other botanicals sourced across three or four suppliers, each ingredient requires identity verification before use. HPLC chemical fingerprinting and DNA barcoding are both used for botanical ID, but they’re not interchangeable — different methods perform better with different plant matrices and processing forms. When you’re rotating suppliers to manage availability or cost, you can’t assume last quarter’s qualification transfers automatically to the new source. Contamination with adulterants (substituted or extended botanicals) remains a persistent problem in the supply chain, and the botanical ingredient market is not uniformly well-regulated upstream.

Heavy metal burden. Botanical ingredients concentrate heavy metals from soil. Lead, arsenic, cadmium, and mercury levels vary considerably by crop origin, soil conditions, and processing method. California’s Prop 65 maximum allowable dose levels are unforgiving: 0.5 µg/day for lead and 10 µg/day for arsenic. A single-herb product with a stable formulation can be tested on a lot-by-lot or periodic basis with reasonable statistical confidence. A custom formulation with variable ingredient ratios creates a different cumulative metal burden for each variant — you can’t extrapolate from a “base formula” heavy metals test and apply it across every combination your algorithm generates.

Microbial risk. Botanical raw materials consistently carry higher initial microbial loads than synthetic ingredients. When a formulation is combining six, eight, or ten botanicals in varying ratios, the total aerobic plate count, yeast/mold levels, and bile-tolerant gram-negative bacterial burden of each finished variant need to be understood. USP <2021> and USP <2022> set the microbial quality standards for dietary supplements, and the limits are the same regardless of how personalized or complex the formulation is. Moisture-sensitive botanicals introduce additional risk when packaged in blended powders intended for on-demand mixing.

Label claim accuracy. Potency verification — confirming that what the label declares is actually present in the product — is the most consumer-visible testing requirement and, for personalized brands, the most obviously consequential. Independent audits from organizations like NSF International have found that approximately 20% of tested dietary supplements fall outside acceptable label potency ranges. That number almost certainly skews higher for novel or variable formulations where assay methods haven’t been specifically developed and validated for the product matrix.

Stability. Every unique formulation combination is, in principle, a distinct stability question. Interactions between ingredients — particularly moisture-sensitive botanicals alongside hygroscopic minerals or amino acids — can affect both potency retention and physical characteristics over shelf life. ICH Q1A(R2) guidance on accelerated stability studies was written for pharmaceutical products, but supplement brands have adopted it as the practical industry standard because FDA has never issued supplement-specific stability guidance. Running even an accelerated 6-month study at 40°C/75% RH on a rotating menu of formulations is logistically demanding and expensive — but without it, the expiration date on the label is a guess.

The Contract Manufacturing Gap

Most personalized supplement brands don’t manufacture anything. They’re working with contract manufacturers under private label arrangements. The brand owns the formulation specification; the CMO runs production. This is a completely legitimate business model — but it comes with a regulatory responsibility that many brands underestimate.

Under 21 CFR Part 111, when a brand contracts out manufacturing operations, the brand remains responsible for ensuring the contracted work meets GMP requirements. That means auditing your CMO, reviewing their testing records, understanding their raw material qualification procedures, and maintaining your own internal quality program. You can’t accept a COA from your contract manufacturer and consider your obligations discharged.

We’ve seen this play out in FDA warning letters issued directly to brands — not the CMOs — for GMP failures in outsourced production. The brand’s name is on the label; the brand owns the compliance obligation. A contract doesn’t transfer that.

Building a Testing Strategy Designed for Variable Formulations

If you’re operating a personalized supplement brand, or planning to enter the space, a functional testing strategy has a few non-negotiable structural requirements.

Component-level testing programs. Qualify your ingredient suppliers through a combination of facility audits, COA review, and independent verification testing at a qualified third-party supplement testing lab. For high-risk botanicals — turmeric, ashwagandha, moringa, and other South Asian agricultural products that consistently show elevated heavy metal levels — independent testing of each incoming lot is warranted regardless of supplier history or supplier COA quality. Supplier data and independent data are not the same thing.

Risk-based formulation grouping. You don’t necessarily need a unique finished-product test for every customer variant. Work with your quality team and your lab partner to identify formulation families: groups of variants that share the same active ingredients within a defined concentration band. Testing that covers the family bracket — worst-case high and low combinations for microbial and metal burden — is defensible and practical. This is an area where a lab with real experience in supplement testing strategy can add genuine value, not just an analytical number.

Third-party verification at an ISO 17025 accredited supplement testing lab. ISO/IEC 17025 accreditation means a lab’s testing methods have been independently validated for technical competence by an accreditation body — in the US, typically A2LA or Perry Johnson Laboratory Accreditation. For personalized supplement brands selling on Amazon or through major retail, third-party COAs from accredited labs are increasingly a baseline requirement, not a nice-to-have. Not all labs hold accreditation, and accreditation scope matters: a lab accredited for heavy metals analysis by ICP-MS may not hold accreditation for botanical identity testing by HPLC or DNA barcoding. Ask specifically about scope.

Accelerated stability on representative variants. Pick the formulation variants with the most ingredient interactions, the highest moisture-sensitive ingredient loads, and the shortest predicted shelf life, and run formal accelerated stability on those. Bracket the broader formulation range with documented scientific rationale. It’s not a complete solution, but it’s far more defensible than assigning a shelf life with no data, and it’s the approach FDA investigators will look for if a product ever comes under scrutiny.

The Gap Is Real — And It’s Getting Harder to Ignore

The personalized nutrition space is generating genuine consumer demand. For brands executing well, it’s also generating meaningful revenue and customer loyalty. But the testing infrastructure at many of these companies is lagging by several years behind the marketing sophistication. That gap creates regulatory exposure, consumer safety risk, and eventually brand risk — when a product fails an independent potency test, triggers an Amazon complaint, or lands on a watchdog organization’s radar.

FDA hasn’t issued specific guidance for personalized supplement formulations, but 21 CFR Part 111 is comprehensive and applies regardless. And the consumer protection argument is straightforward: if you’re making a health claim to a specific individual based on their personal health profile, the product needs to actually contain what you told them it contains.

Getting there requires a quality program designed from the beginning for variable formulations — not one retrofitted from a standard supplement playbook after a problem surfaces.

---

Written by Nour Abochama, Vice President of Operations, Qalitex Laboratories. Learn more about our team

Talk to our team about your testing needs. Contact us

Related from our network

• FDA GMP Audit Readiness for Supplement Manufacturers — Aurora TIC covers the regulatory consulting side of 21 CFR Part 111 compliance, from SOP development to mock FDA inspection preparation.
• Raw Material Supplier Qualification and COA Verification — Ayah Labs specializes in B2B ingredient testing and supplier qualification programs for dietary supplement raw materials.